target
therapi
current
limit
patient
hepatocellular
carcinoma
hcc
due
lack
suitabl
target
kinas
play
pivot
role
mani
cellular
biolog
process
wherea
dysregul
kinas
may
lead
variou
diseas
particularli
cancer
howev
role
kinas
hcc
malign
remain
unclear
studi
employ
kinom
small
interf
rna
sirna
librari
compris
kinaserel
gene
screen
whether
kinas
essenti
cell
prolifer
variou
hcc
cell
line
kinom
sirna
librari
screen
found
crucial
gene
hcc
cell
prolifer
pharmacolog
genet
ablat
diminish
growth
migrat
invas
hcc
cell
includ
primari
hcc
cell
stabl
knockdown
attenu
tumor
format
spheroid
cell
cultur
model
tumor
xenograft
mous
model
addit
silenc
reduc
phosphoryl
express
mammalian
target
rapamycin
mtor
hcc
cell
express
posit
correl
mtor
express
tumor
patient
hcc
higher
coexpress
mtor
significantli
associ
poor
prognosi
hcc
taken
togeth
result
reveal
axi
might
promot
tumorigenesi
malign
provid
potenti
marker
therapeut
target
hcc
patient
hepatocellular
carcinoma
hcc
one
preval
malign
tumor
major
caus
cancerrel
death
worldwid
cur
treatment
patient
hcc
includ
surgic
resect
liver
transplant
radiofrequ
ablationpercutan
ethanol
inject
howev
patient
earlystag
hcc
elig
cur
treatment
system
chemotherapi
challeng
patient
compromis
liver
function
present
hcc
patient
sorafenib
first
target
drug
clinic
approv
use
patient
advanc
hcc
major
target
sorafenib
serinethreonin
kinas
involv
rasrafmekmitogenactiv
protein
kinas
signal
mapk
cascad
although
sorafenib
effici
inhibit
activ
low
dose
half
maxim
inhibitori
concentr
valu
nm
increas
number
report
shown
sorafenib
also
inhibit
sever
receptor
tyrosin
kinas
vascular
endotheli
growth
factor
receptor
vegfr
plateletderiv
growth
factor
receptor
pdgfr
fibroblast
growth
factor
receptor
moreov
sorafenib
show
limit
surviv
benefit
larg
random
phase
iii
studi
low
respons
rate
like
due
molecul
involv
epithelialmesenchym
transit
cancer
stem
tumor
microenviron
drug
resist
effect
therapeut
target
hcc
current
unavail
demonstr
urgent
need
identifi
suitabl
molecul
overcom
press
issu
kinas
crucial
upstream
regul
signal
pathway
requir
homeostasi
normal
cell
dysregul
oncogen
kinas
either
overexpress
overactiv
highli
associ
tumorigenesi
migrat
invas
drug
resist
addit
involv
aforement
kinas
hcc
mani
kinas
reportedli
associ
tumor
progress
hcc
aurora
kinas
aurka
associ
cancer
metastasi
stem
hcc
cell
particularli
hcc
cell
mammalian
target
rapamycin
mtor
overexpress
hcc
express
correl
poor
differenti
prognosi
focal
adhes
kinas
upregul
protooncogen
hcc
cell
growth
gene
concomitantli
express
higher
level
hcc
nontumor
liver
gene
fusion
activ
prkaca
kinas
promot
tumorigenesi
fibrolamellar
hcc
mice
moreov
annexin
activ
jnk
growth
hcc
cell
particularli
liver
cancer
stem
cell
although
mani
kinas
play
pivot
role
signal
pathway
associ
hcc
tumorigenesi
inhibitor
target
kinas
larg
benefici
patient
hcc
indic
littl
known
kinas
hcc
therapi
studi
employ
kinom
sirna
librari
identifi
potenti
kinas
requir
surviv
hcc
cell
found
mitogenactiv
protein
kinas
kinas
kinas
appear
essenti
growth
metastat
characterist
hcc
cell
genet
pharmacolog
target
attenu
tumor
cell
growth
spheroid
cell
cultur
xenograft
mous
model
addit
express
posit
correl
mtor
express
high
coexpress
abbrevi
mitogenactiv
protein
kinas
kinas
kinas
hcc
hepatocellular
carcinoma
mtor
mammalian
target
rapamycin
transform
growth
factor
beta
mtor
associ
poor
surviv
patient
hcc
taken
togeth
result
suggest
might
potenti
target
futur
develop
target
therapi
hcc
cell
cultur
transfect
stabl
select
hcc
cancer
cell
line
american
type
cultur
collect
manassa
va
cultur
dulbecco
modifi
eagl
medium
dmem
fetal
bovin
serum
fb
streptomycin
iu
penicillin
lglutamin
c
co
air
primari
cell
cultur
hcc
cell
isol
dr
hungwei
pan
surgic
resect
hcc
patient
approv
kaohsiung
veteran
gener
hospit
irb
protocol
primari
hcc
cell
cultur
supplement
basic
fibroblast
growth
factor
ngml
epiderm
growth
factor
ngml
lglutamin
mml
insulin
growth
factor
ul
supplement
spheroid
cell
cultur
hcc
cell
seed
densiti
cellswel
nanocultur
plate
cm
scivax
corpor
kanagawa
japan
cell
cultur
day
spheroid
format
diamet
mm
gene
knockdown
sirna
cell
transfect
nm
scrambl
sirna
sirna
src
kinas
dhamacon
lafayett
co
h
use
lipofectamin
rnaimax
invitrogen
carlsbad
ca
lentiviru
infect
cell
seed
plate
transfect
scrambl
short
hairpin
rna
shrna
shrna
aurka
pololik
kinas
use
lipofectamin
invitrogen
h
transfect
cell
wash
medium
incub
h
cell
debri
remov
filter
supernat
use
infect
hcc
cell
polybren
sigmaaldrich
usa
h
cell
maintain
cultur
medium
puromycin
medium
refresh
everi
day
obtain
stabl
cell
line
knockdown
effici
confirm
realtim
pcr
mrna
level
gene
cell
amplifi
sybr
green
master
mix
appli
biosystem
analyz
steppneplu
system
appli
biosystem
usa
describ
previous
primer
sequenc
use
gene
express
shown
follow
forward
revers
gccgaagctctacaata
gapdh
forward
revers
normal
control
primer
sequenc
gene
provid
upon
request
cell
prolifer
assay
sirna
screen
cell
harbor
luciferas
plasmid
seed
well
white
plate
contain
nm
scrambl
sirna
kinom
sirna
librari
sirna
gene
thermo
fisher
scientif
waltham
rnaimax
invitrogen
h
cell
mix
celltit
glo
promega
madison
wi
luminesc
signal
monitor
reflect
cell
prolifer
measur
atp
level
addit
cell
treat
merck
kenilworth
nj
h
mix
celltit
glo
promega
luminesc
signal
read
fluoroskan
ascent
fl
reader
thermo
fisher
scientif
clonogen
assay
hcc
cell
seed
plate
densiti
cellswel
describ
previous
cultur
medium
replac
everi
day
day
coloni
format
cell
coloni
fix
paraformaldehyd
stain
crystal
violet
wv
count
determin
cytotox
wound
heal
assay
silenc
cell
dmem
seed
cultur
insert
ibidi
inc
planegg
germani
h
subsequ
cultur
insert
remov
h
cell
fix
measur
migrat
distanc
transwel
invas
assay
perform
use
pore
insert
greiner
bioon
stroud
uk
describ
previous
briefli
silenc
cell
seed
top
chamber
matrigelco
transwel
plate
dmem
contain
fb
invas
cell
fix
stain
crystal
violet
invad
cell
observ
microscop
magnif
quantifi
imagej
softwar
cell
lyse
ripa
buffer
describ
previous
protein
separ
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
transfer
onto
nitrocellulos
membran
membran
block
bovin
serum
albumin
incub
follow
primari
antibodi
c
overnight
cell
signal
technolog
danver
antiphosphoryl
p
mtor
cell
signal
technolog
antimtor
cell
signal
technolog
antipampk
cell
signal
technolog
antiampk
cell
signal
technolog
cell
signal
technolog
antiraptor
cell
signal
technolog
antiactb
sigmaaldrich
st
loui
mo
protein
probe
secondari
antibodi
licor
lincoln
ne
room
temperatur
h
scan
analyz
protein
express
odyssey
r
imag
system
licor
fiveweekold
immunodefici
mice
nunu
femal
purchas
acclim
day
prior
tumor
implant
cell
stabli
harbor
scrambl
shrna
shrna
mix
matrigel
implant
mice
tumor
size
measur
everi
day
calcul
formula
larger
diamet
smaller
diamet
anim
experi
approv
institut
anim
care
use
committe
kaohsiung
veteran
gener
hospit
tumor
resect
sacrif
mice
weigh
fix
paraformaldehyd
immunohistochem
analysi
retrospect
cohort
studi
tissu
microarray
hcc
patient
purchas
us
biomax
use
determin
correl
kinas
hit
prognosi
colorect
tissu
analyz
immunohistochem
stain
tissu
section
stain
antibodi
abcam
cambridg
uk
follow
horseradish
peroxidaseconjug
secondari
antibodi
observ
protein
level
tumor
adjac
normal
cell
tumor
cell
within
microscop
field
count
allr
score
system
base
sum
proport
score
intens
score
estim
averag
stain
intens
score
cell
neg
weak
express
moder
express
strong
express
proport
score
neg
subsequ
data
analysi
kinas
express
level
score
consid
low
wherea
score
categor
high
data
report
mean
standard
error
mean
sem
three
independ
experi
result
coloni
format
migrat
invas
perform
nonparametr
student
ttest
data
analyz
use
analysi
varianc
anova
tukey
posthoc
test
analyz
xenograft
tumor
size
gene
express
hcc
patient
dataset
obtain
cancer
genom
atla
tcga
databas
http
cancergenomenihgov
wilcoxon
signedrank
test
use
evalu
differ
level
kinas
tumor
correspond
tumor
adjac
normal
tissu
cutoff
gene
protein
express
level
accord
receiv
oper
characterist
roc
curv
divid
high
low
group
cumul
surviv
curv
estim
use
kaplanmei
method
univari
multivari
cox
proport
hazard
model
use
crude
adjust
hazard
ratio
respect
p
consid
signific
although
hepat
b
viru
hbv
one
major
risk
factor
hcc
aim
present
studi
identifi
suitabl
kinas
therapeut
target
type
hcc
certain
type
hcc
thu
evalu
kinas
requir
hcc
cell
prolifer
two
hbvneg
hcc
cell
line
transfect
kinom
sirna
librari
determin
effect
gene
hcc
cell
prolifer
figur
top
rank
hit
reveal
silenc
gene
inhibit
cell
prolifer
cell
pool
sirna
gene
transfect
hbvneg
posit
hcc
cell
line
valid
whether
kinas
essenti
cell
prolifer
differ
type
hcc
cell
figur
suppress
effect
sirna
top
five
gene
cell
prolifer
consist
variou
hcc
cell
line
examin
stabl
knockdown
gene
effect
diminish
gene
express
coloni
format
cell
wherea
gene
knockdown
aurka
inhibit
coloni
format
cell
figur
role
aurka
hcc
report
previous
howev
serv
tumor
promot
suppressor
liver
cell
still
controversi
thu
select
valid
effect
coloni
format
use
transient
transfect
sirna
figur
transient
gene
silenc
significantli
suppress
coloni
format
cell
furthermor
knockdown
littl
effect
g
phase
arrest
cell
cycl
cell
figur
examin
involv
metastat
characterist
cell
hcc
cell
line
transfect
sirna
migrat
invas
assay
migrat
significantli
attenu
hcc
cell
compar
cell
transfect
scrambl
sirna
figur
transient
knockdown
inhibit
invas
abil
cell
figur
similar
result
transient
knockdown
stabl
knockdown
significantli
inhibit
migrat
invas
hcc
cell
figur
e
evalu
whether
kinas
activ
involv
cancer
malign
hcc
cell
treat
inhibitor
determin
effect
cell
prolifer
coloni
format
migrat
invas
figur
significantli
reduc
growth
mobil
hcc
cell
inspect
requir
migrat
invas
hbvposit
hcc
cell
well
interestingli
silenc
effect
cell
invas
hbvposit
cell
line
promot
cell
migrat
cell
figur
addit
treatment
reduc
migrat
invas
wherea
increas
cell
invas
cell
figur
result
suggest
might
import
metastat
characterist
certain
type
hcc
cell
assess
precis
effect
tumor
transient
stabli
knock
sirna
shrna
hcc
cell
respect
cell
seed
nanocultur
plate
grow
spheroid
mimic
tumor
format
vivo
figur
contrast
cell
transfect
scrambl
control
sphere
volum
cell
prolifer
significantli
decreas
hcc
cell
figur
c
inspect
effect
tumor
format
vivo
cell
stabli
harbor
scrambl
shrna
shrna
inject
subcutan
nude
mice
figur
volum
xenograft
tumor
measur
clearli
show
growth
hcc
cell
much
slower
control
cell
figur
e
likewis
tumor
weight
significantli
lower
hcc
tumor
figur
knockdown
effici
xenograft
tumor
confirm
immunohistochemistri
level
protein
reduc
tumor
figur
confirm
hcc
cell
lack
exhibit
arrest
tumor
growth
vivo
found
promot
cell
growth
metastat
characterist
cell
cultur
model
determin
whether
express
correl
tumor
develop
patient
hcc
tissu
microarray
contain
tumor
adjac
normal
tumor
metastat
tissu
use
examin
express
immunohistochemistri
figur
level
protein
higher
tumor
tissu
tumor
adjac
normal
tissu
p
level
protein
slightli
higher
metastat
tumor
tissu
primari
tumor
tissu
figur
c
high
protein
level
tumor
tissu
poor
overal
surviv
figur
analyz
express
level
hcc
dataset
obtain
tcga
high
express
associ
shorter
overal
surviv
wherea
effect
diseasefre
surviv
figur
f
inspect
role
cancer
cell
surviv
primari
hcc
cell
transfect
scrambl
sirna
sirna
silenc
inhibitor
reduc
prolifer
primari
hcc
cell
includ
hbvneg
hcvposit
hbvposit
hcv
neg
cell
figur
h
requir
protein
trigger
activ
key
transcript
factor
tumor
initi
malign
inde
knockdown
attenu
effect
tumor
necrosi
factor
tnf
stimul
transcript
activ
cell
data
shown
correl
tab
express
overal
surviv
patient
hcc
also
inspect
tabl
high
coexpress
associ
shorter
surviv
tabl
adjust
hazard
ratio
ahr
p
similar
result
observ
patient
high
coexpress
level
ahr
p
ahr
p
nevertheless
sinc
result
report
previous
cancer
cell
select
screen
regular
medium
without
stimul
set
asid
moreov
inactiv
induc
ampk
activ
diminish
phosphoryl
mtor
skelet
muscl
cell
thu
inspect
involv
potenti
downstream
effector
mtor
tumor
malign
hcc
cell
interestingli
knockdown
decreas
mtor
phosphoryl
protein
level
without
affect
ampk
phosphoryl
hcc
cell
figur
express
mtor
mrna
also
decreas
hcc
cell
figur
tcga
data
analysi
show
express
posit
correl
mtor
level
figur
associ
surviv
express
alon
combin
mtor
express
evalu
univari
multivari
cox
proport
hazard
model
tabl
high
express
associ
poor
overal
surviv
patient
hcc
ahr
p
coexpress
either
high
mtor
low
low
mtor
high
associ
shorter
overal
surviv
ahr
p
coexpress
high
mtor
high
much
wors
overal
surviv
ahr
p
howev
neither
express
alon
combin
mtor
express
correl
diseasefre
surviv
similarli
kaplanmei
plot
show
high
coexpress
mtor
associ
significantli
shorter
overal
surviv
figur
wherea
correl
diseasefre
surviv
figur
suggest
axi
involv
tumor
malign
recurr
patient
hcc
target
therapi
type
treatment
block
specif
oncogen
molecul
diminish
cancer
growth
invas
trastuzumab
herceptin
human
epiderm
growth
factor
receptor
breast
cancer
imatinib
gleevec
bcrabl
chronic
myelogen
leukemia
bevacizumab
avastin
vascular
endothelia
growth
factor
vegf
colorect
lung
cancer
result
indic
mani
kinas
associ
tumor
develop
malign
variou
cancer
type
sorafenib
inhibit
multipl
kinas
includ
raf
vegfr
pdgfr
limit
benefit
popul
hcc
patient
moreov
singl
kinas
report
effect
target
patient
hcc
herein
comprehens
screen
two
hcc
cell
line
kinom
sirna
librari
potenti
therapeut
target
hcc
studi
report
follow
find
first
genet
pharmacolog
ablat
attenu
hcc
cell
growth
twodimension
spheroid
cell
cultur
well
xenograft
tumor
second
depriv
inhibit
migrat
invas
hcc
cell
third
express
higher
tumor
tissu
high
express
alon
combin
downstream
regul
mtor
associ
poor
surviv
patient
hcc
kinomewid
screen
potenti
target
hcc
sirna
librari
knockdown
sever
identifi
kinas
suffici
block
cell
prolifer
variou
hcc
cell
line
includ
hbvposit
neg
hcc
cell
line
spheroid
cell
cultur
result
also
show
silenc
inhibit
sphere
format
hbvneg
hbvposit
cell
moreov
cell
wildtyp
wherea
cell
mutant
gene
delet
two
cell
line
silenc
diminish
cell
growth
hcc
cell
line
without
wildtyp
mutant
impli
effect
cell
prolifer
might
hbvand
manner
interestingli
gene
knockdown
kinas
show
stronger
inhibitori
effect
cell
mutant
delet
cell
ye
result
suggest
inactiv
might
involv
kinasemedi
tumorigenesi
warrant
investig
hand
opposit
effect
migrat
cell
incub
overnight
cultur
insert
insert
remov
assess
cell
migrat
presenc
absenc
e
effect
invas
hcc
cell
determin
matrigelco
transwel
filter
quantifi
result
migrat
invas
f
express
mean
sem
three
independ
experi
p
p
p
invas
observ
cell
cell
result
suggest
factor
may
interfer
signal
cell
migrat
invas
requir
studi
elucid
addit
nuclear
receptor
bind
protein
aurka
report
import
hcc
aurka
express
level
elev
tumor
tissu
compar
adjac
normal
tissu
patient
hcc
silenc
arrest
cell
cycl
phase
induc
apoptosi
knockdown
aurka
reduc
postradiotherapi
invas
hcc
moreov
activ
mutat
hcc
patient
inhibitor
mtor
inhibit
cell
prolifer
enhanc
chemosensit
hcc
cell
sorafenib
result
suggest
screen
platform
could
use
find
new
therapeut
target
hcc
screen
sirna
librari
contrast
express
lower
tumor
tissu
high
express
associ
better
prognosi
chemosensit
sorafenib
suggest
serv
tumor
suppressor
nevertheless
current
data
show
transient
stabl
knockdown
diminish
prolifer
hcc
cell
requir
studi
elucid
role
hcc
member
famili
also
known
transform
growth
factor
tgf
kinas
modul
sever
cytokin
tolllik
receptor
b
cell
receptor
cytokin
induc
format
activ
complex
via
tnf
receptor
associ
factor
associ
nterminu
cterminu
respect
full
activ
interact
kinas
mapk
enhanc
transcript
activ
associ
inflamm
tumorigenesi
gene
silenc
enhanc
sensit
cancer
cell
normal
epitheli
cell
chemotherapeut
drug
inhibitor
block
activ
increas
chemotherapeut
efficaci
pancreat
cancer
cell
convers
condit
knockout
liver
parenchym
cell
mice
induc
hepatocyt
dysplasia
earlyonset
hepatocarcinogenesi
present
studi
express
much
higher
tumor
tissu
adjac
normal
tissu
associ
poor
surviv
hcc
patient
gene
silenc
block
hcc
cell
growth
cell
cultur
tumor
xenograft
mous
model
suggest
low
level
may
essenti
normal
physiolog
function
hepatocyt
much
may
caus
inflamm
promot
hcc
particularli
cytokineelev
condit
addit
cytokin
activ
variou
virus
also
known
highrisk
factor
hepatocarcinogenesi
hcc
includ
hbv
hepat
c
viru
hcv
x
protein
hbv
activ
ikk
activ
mtor
downstream
effector
hcv
infect
increas
express
lipogenesi
core
protein
trigger
activ
gene
express
inflammatori
cytokin
crucial
factor
activ
complex
format
howev
miss
link
hbvhcv
activ
hcc
develop
need
studi
elucid
moreov
reportedli
phosphoryl
mtor
regul
mitochondri
function
mtor
overexpress
approxim
hcc
patient
associ
poor
differenti
prognosi
mtor
inhibitor
current
test
clinic
trial
patient
hcc
present
data
show
silenc
reduc
phosphoryl
mtor
also
diminish
protein
mrna
level
high
coexpress
level
mtor
significantli
associ
poor
overal
diseasefre
surviv
patient
hcc
compar
low
express
level
nevertheless
patient
number
n
high
coexpress
level
mtor
overal
surviv
larg
enough
shown
tabl
studi
may
need
larger
cohort
hcc
verifi
associ
gene
overal
surviv
addit
decreas
ampk
activ
wherea
increas
phosphoryl
mtor
ampk
phosphoryl
regulatoryassoci
protein
mtor
raptor
inactiv
mtor
current
result
show
silenc
reduc
mtor
phosphoryl
without
chang
phosphoryl
ampk
raptor
involv
mtor
activ
cardiomyocyt
rais
possibl
may
regul
mtor
activ
although
molecular
mechan
affect
mtor
express
requir
studi
result
indic
might
potenti
diagnost
marker
therapeut
target
futur
drug
develop
hcc
studi
carri
approv
institut
anim
care
use
committe
kaohsiung
veteran
gener
hospit
jsc
wlt
pfl
cwl
perform
experi
except
experi
perform
hht
figur
ygg
figur
tumor
xenograft
mous
experi
perform
chl
cw
prepar
figur
perform
statist
analys
interpret
data
wrote
manuscript
